Desulfovibrio species are potentially important in regressive autism

Medical Hypotheses

Volumn 77, Issue 2, 2011, Pages 270-274

  Finegold, Sydney M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;

ARTICLE; AUTISM; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CHILDHOOD; CLOSTRIDIUM; DESULFOVIBRIO; HUMAN; NONHUMAN; PATHOGENESIS; PILOT STUDY; REAL TIME POLYMERASE CHAIN REACTION; REGRESSIVE AUTISM; SIBLING;

AUTISTIC DISORDER; DESULFOVIBRIO; FECES; HUMANS; MODELS, BIOLOGICAL; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

BACILLUS (BACTERIUM); BACTERIA (MICROORGANISMS); CLOSTRIDIA; DESULFOVIBRIO;

EID: 79960629891     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.04.032     Document Type: Article

References (16)

1. Hollander E., Anagnostou E. Clinical manual for the treatment of autism 2008, American Psychiatric Publishing, Arlington, VA.
2. Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010.
3. Herbert M.R., Russo J.P., Yang S., Roohi J., Blaxill M., Kahler S.G., et al. Autism and environmental genomics. Neurotoxicology 2006, 27:671-684.
4. Centers for Disease Control. Autism and Developmental Disabilities Monitoring (ADDM) Network. Centers for Disease Control. 2008. <>. http://www.cdc.gov/ncbddd/autism/addm.htm.
5. HSPH. Autism Has High Costs to U.S. Society. Harvard School of Public Health. 2006. <>. http://www.hsph.harvard.edu/news/press-releases/2006-releases/press04252006.html.
6. Sandler R.H., Finegold S.M., Bolte E.R., Buchanan C.P., Maxwell A.P., Vaisanen M.L., et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000, 15:429-435.
7. Finegold S.M., Molitoris D., Song Y., Liu C., Väisänen M.-L., Bolte E., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35(Supp. 1):S6-S16.
8. Parracho H.M., Bingham M.O., Gibson G.R., McCartney A.L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 2005, 54:987-991.
9. Finegold S.M. Therapy and epidemiology of autism - clostridial spores as key elements. Med Hypotheses 2008, 70:508-511.
10. Song Y., Liu C., Finegold S.M. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol 2004, 70:6459-6465.
11. Finegold S.M., Dowd S.E., Gontcharova V., Liu C., Henley K.E., Wolcott R.D., et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe 2010, 16:444-453.
12. MacFabe D.F., Rodriguez-Capote K., Hoffman J.E., Franklin A.E., Mohammad-Asef Y., Taylor A.R., et al. A novel rodent model of autism: intraventricular infusions of propionic acid increase locomotor activity and induce neuroinflammation and oxidative stress in discrete regions of adult rat brain. Am J Biochem Biotechnol 2008, 4:146-166.
13. Niehus R., Lord C. Early medical history of children with autism spectrum disorders. Dev Behav Pediatr 2006, 27(2):S120-S127.
14. Emanuele E., Orsi P., Boso M., Broglia D., Brondino N., Barale F., et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett 2010, 471:162-165.
15. James S.J., Cutler P., Melnyk S., Jernigan S., Janak L., Gaylor D.W., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004, 80:1611-1617.
16. Waring R.H., Klovrza L.V. Sulphur metabolism in autism. J Nutr Environ Med 2000, 10:25-32.